.png)
Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.
Jax DiEugenio
Advertisement
Jax DiEugenio is an assistant editor for OncLive.
Articles by Jax DiEugenio
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
2
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
5